This study highlights the interplay between atherogenic status (e.g., elevated LDL-C), systemic inflammation (e.g., IL-6, hs-CRP), and coagulation-related endothelial dysfunction (e.g., sCD40-L, VCAM-1), which collectively contribute to CMVO pathogenesis. This evidence concerns the gene IL6 and endothelial dysfunction.